The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. The metric has seen a significant loss of -42.43% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -63.31%. Over the past 30 days, the price of TCRX has fallen by 9.38%. And in the last five days, it has surged by 22.38%.
Tscan Therapeutics Inc’s market performance has been unstable in recent times. The company’s stock hit a 1-year high of $9.29 on 06/13/24 and a low of $1.02 for the same time frame on 04/09/25.
52-week price history of TCRX Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Tscan Therapeutics Inc’s current trading price is -81.16% away from its 52-week high, while its distance from the 52-week low is 71.57%. The stock’s price range during this period has varied between$1.02 and $9.29. The Tscan Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.18 million for the day, a figure considerably higher than their average daily volume of 0.57 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Tscan Therapeutics Inc (TCRX) has experienced a quarterly decline of -13.37% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 99.03M and boasts a workforce of 194 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.7874, with a change in price of -1.2600. Similarly, Tscan Therapeutics Inc recorded 499,362 in trading volume during the last 100 days, posting a change of -41.86%.
TCRX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for TCRX stands at 0.46. Similarly, the long-term debt-to-equity ratio is also 0.44.
TCRX Stock Stochastic Average
Tscan Therapeutics Inc’s raw stochastic average for the past 50 days is presently 98.65%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 100.00%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 74.96% and 65.63%, respectively.
